We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+34.9%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$123M
AUM Growth
+$21.1M
Cap. Flow
+$8.21M
Cap. Flow %
6.67%
Top 10 Hldgs %
62.1%
Holding
78
New
19
Increased
23
Reduced
16
Closed
20

Top Buys

Rank Stock Value
1
VSTM icon
Verastem
VSTM
+$9.75M
2
EOLS icon
Evolus
EOLS
+$4.83M
3
OABI icon
OmniAb
OABI
+$3.92M
4
XFOR icon
X4 Pharmaceuticals
XFOR
+$2.72M
5
ABEO icon
Abeona Therapeutics
ABEO
+$2.57M

Top Sells

Rank Stock Value
1
INDV icon
Indivior Pharmaceuticals
INDV
+$5.23M
2
ITOS
iTeos Therapeutics
ITOS
+$3.09M
3
ANIP icon
ANI Pharmaceuticals
ANIP
+$2.52M
4
ENTA icon
Enanta Pharmaceuticals
ENTA
+$2.39M
5
ANIK icon
Anika Therapeutics
ANIK
+$2.02M

Sector Composition

Rank Sector Weight
1 Healthcare 99.76%
2 Financials 0.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XERS icon
76
Xeris Biopharma Holdings
XERS
$1.4B
– –
-205,100
Closed -$958K
YMAB
77
DELISTED
Y-mAbs Therapeutics
YMAB
– –
-285,300
Closed -$1.29M
CLYM
78
Climb Bio
CLYM
$676M
– –
-116,147
Closed -$144K
1 2 3
4

Similar funds

ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
TAM
Tabor Asset Management New York $249M AUM 48.59% 1-Year Est. Return

Stonepine Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Stonepine Capital Management held 78 positions worth $123M, up 21% from $102M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Stonepine Capital Management deployed $8.21M of net new capital in Q3 2025, opening 19 new positions and adding to 23 existing holdings. Its largest new stake was OmniAb: 2,142,857 shares worth $3.43M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Indivior Pharmaceuticals, an estimated $5.23M trimmed.

  • Stonepine Capital Management's largest Q3 2025 buy was OmniAb: 2,142,857 shares worth $3.43M.
  • Stonepine Capital Management added most to Verastem in Q3 2025, an estimated $9.75M increase.
  • Stonepine Capital Management's biggest Q3 2025 reduction was Indivior Pharmaceuticals, cutting an estimated $5.23M.
  • Stonepine Capital Management fully exited iTeos Therapeutics in Q3 2025, selling an estimated $3.09M.
  • Stonepine Capital Management's ten largest holdings make up 62% of its $123M portfolio in Q3 2025.
  • Stonepine Capital Management opened 19 new positions and closed 20 in Q3 2025.
  • Stonepine Capital Management's portfolio value rose 21% quarter-over-quarter to $123M.

Based on Stonepine Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.